NI200700222A - N-hydroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona de desacetilasa, su preparación y su uso en formulaciones farmacéuticas. - Google Patents

N-hydroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona de desacetilasa, su preparación y su uso en formulaciones farmacéuticas.

Info

Publication number
NI200700222A
NI200700222A NI200700222A NI200700222A NI200700222A NI 200700222 A NI200700222 A NI 200700222A NI 200700222 A NI200700222 A NI 200700222A NI 200700222 A NI200700222 A NI 200700222A NI 200700222 A NI200700222 A NI 200700222A
Authority
NI
Nicaragua
Prior art keywords
omega
inhibitors
substituted
hydroxiamids
triciclic
Prior art date
Application number
NI200700222A
Other languages
English (en)
Inventor
Antonio Guidi
Danilo Giannotti
Nicholas Harmat
Tula Dimoulas
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of NI200700222A publication Critical patent/NI200700222A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen nuevas N-hidroxiamidas de ácidos n-alquil carboxílicos omega sustituidos con oportuno sistema tricíclico caracterizado por un anillo central de siete miembros que tienen la actividad como inhibidores de la histona desacetilasa (HDAC).
NI200700222A 2005-03-15 2007-08-23 N-hydroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona de desacetilasa, su preparación y su uso en formulaciones farmacéuticas. NI200700222A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000042 IT1362675B (it) 2005-03-15 2005-03-15 N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche

Publications (1)

Publication Number Publication Date
NI200700222A true NI200700222A (es) 2008-07-24

Family

ID=36676439

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700222A NI200700222A (es) 2005-03-15 2007-08-23 N-hydroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona de desacetilasa, su preparación y su uso en formulaciones farmacéuticas.

Country Status (22)

Country Link
US (1) US20080275023A1 (es)
EP (1) EP1863776A1 (es)
JP (1) JP2008533088A (es)
KR (1) KR20080003336A (es)
CN (1) CN101142197A (es)
AP (1) AP2007004170A0 (es)
AR (1) AR053171A1 (es)
AU (1) AU2006222883A1 (es)
BR (1) BRPI0608549A2 (es)
CA (1) CA2600521A1 (es)
CO (1) CO6321131A2 (es)
EA (1) EA013015B1 (es)
IL (1) IL185879A0 (es)
IT (1) IT1362675B (es)
MA (1) MA29673B1 (es)
MX (1) MX2007011071A (es)
NI (1) NI200700222A (es)
NO (1) NO20075229L (es)
SA (1) SA06270133B1 (es)
TW (1) TW200719900A (es)
WO (1) WO2006097449A1 (es)
ZA (1) ZA200708754B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
BRPI0718089A2 (pt) * 2006-10-28 2013-11-05 Methylgene Inc Composto, uso do composto, composição, e, métodos para inibir histona desacetilase e para tratar uma doença de expansão da poliglutamina
AU2013205135B2 (en) * 2006-10-28 2015-11-05 Forum Pharmaceuticals Inc. Inhibitors of histone deacetylase
AU2007332867B2 (en) * 2006-12-11 2012-02-16 Merck Sharp & Dohme Corp. Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
JP2011102240A (ja) * 2008-02-29 2011-05-26 Univ Of Tokyo 三環性化合物
US8202989B2 (en) 2009-01-12 2012-06-19 Council Of Scientific And Industrial Research One step process for the preparation of substituted 5, 10-dihydrodibenzo [b,e][1, 4]diazepine-11-ones
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
RU2519546C1 (ru) * 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
CA2901493A1 (en) 2013-02-19 2014-08-28 Icahn School Of Medicine At Mount Sinai Tricyclic heterocycles as anticancer agents
CN106458916A (zh) 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
US9937186B2 (en) 2014-03-11 2018-04-10 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
WO2016083276A1 (de) 2014-11-25 2016-06-02 Bayer Pharma Aktiengesellschaft Substituierte pyridobenzodiazepinon-derivate und ihre verwendung
WO2016089797A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10086000B2 (en) 2014-12-05 2018-10-02 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
EP3226689B1 (en) 2014-12-05 2020-01-15 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US10221158B2 (en) 2015-09-09 2019-03-05 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
EP3347355B1 (en) 2015-09-09 2022-07-13 Icahn School of Medicine at Mount Sinai Heterotricyclic sulfonamides as anti-cancer agents
WO2017044571A1 (en) * 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
CN105806973B (zh) * 2016-03-10 2019-01-18 中国医学科学院肿瘤医院 Uplc-ms/ms法测定人血浆中莎巴比星及其代谢产物m3的血药浓度
KR102243465B1 (ko) * 2019-08-05 2021-04-22 리퓨어생명과학 주식회사 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
KR102301274B1 (ko) * 2019-08-05 2021-09-14 리퓨어생명과학 주식회사 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
WO2023020416A1 (zh) * 2021-08-16 2023-02-23 勤浩医药（苏州）有限公司 三环化合物、包含其的药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033110B2 (ja) * 1977-09-12 1985-08-01 帝国臓器製薬株式会社 ジベンズアゼピン誘導体
JPS53121780A (en) * 1977-04-01 1978-10-24 Teikoku Hormone Mfg Co Ltd Dibenzazepin derivatives and process for their preparation
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
KR20050110612A (ko) * 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체

Also Published As

Publication number Publication date
TW200719900A (en) 2007-06-01
ITFI20050042A1 (it) 2006-09-16
EA200701969A1 (ru) 2008-02-28
WO2006097449A1 (en) 2006-09-21
BRPI0608549A2 (pt) 2010-01-12
SA06270133B1 (ar) 2009-05-16
CN101142197A (zh) 2008-03-12
ZA200708754B (en) 2008-10-29
EP1863776A1 (en) 2007-12-12
NO20075229L (no) 2007-11-08
AU2006222883A1 (en) 2006-09-21
CA2600521A1 (en) 2006-09-21
EA013015B1 (ru) 2010-02-26
JP2008533088A (ja) 2008-08-21
MX2007011071A (es) 2007-10-08
AP2007004170A0 (en) 2007-10-31
KR20080003336A (ko) 2008-01-07
CO6321131A2 (es) 2011-09-20
MA29673B1 (fr) 2008-08-01
IT1362675B (it) 2009-06-25
US20080275023A1 (en) 2008-11-06
IL185879A0 (en) 2008-01-06
AR053171A1 (es) 2007-04-25

Similar Documents

Publication Publication Date Title
NI200700222A (es) N-hydroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona de desacetilasa, su preparación y su uso en formulaciones farmacéuticas.
CR9430A (es) N-hidroxiamidas omega-sustituidas con grupos triciclos como inhibidores de histona desacetilasa, su preparacion y uso en formulaciones farmaceuticas
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
BR112015011672A2 (pt) sistema protético para substituição de válvula cardíaca
CL2013000715A1 (es) Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih.
BRPI0810552A2 (pt) Composição de substância ativa, processos para preparar uma composição de substância ativa, e para preparar sementes contenda substância ativa, uso da composição de substância ativa, sementes, e, composição aquosa.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
UY28673A1 (es) Planta de maiz mon88017 y composiciones y metodos de deteccion de la misma
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
FR2954315B1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
CL2008001274A1 (es) Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
CL2007002617A1 (es) Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
CL2008000121A1 (es) Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta.
BRPI0814529A2 (pt) Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
ECSP11011076A (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
FR2961814B1 (fr) Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
EA201190168A1 (ru) Терапевтические применения фракций мастиковой смолы
CL2011002522A1 (es) Compuestos derivados de (piran-) o (tiopiran-)quinazolinadiona, inhibidores de fosfodiesterasa 7 (pde7); procedimiento de preparacion; composicicion farmaceutica; y uso para tratar una enfermedad inflamatoria, inmunoinflamatoria, cardiovascular, del sistema nervioso central y/o periferico.
TW200724529A (en) Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
SV2006002220A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd
BR112015023399A8 (pt) inibidores de hdac, seu uso e composição farmacêutica
FR2949782B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
BRPI0820388A2 (pt) Molécula concatenada para a modulação da atividade do sistema imunológico humano e animal, composição, kit, fármaco e uso
CL2009001150A1 (es) Compuestos derivados de n-(2-amino-fenil)-acrilamidas, inhibidor de la histona-desacetilasa (hdac); procedimiento de preparacion; composicion faramceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.